Insider

CVS Health Corp

CVS Health Care · 1 analysis · 3 expectations tracked

CVS Health reported $108B in revenue (+5.4% YoY), compared with a +7.2% median across covered Health Care peers. Insider tracks 3 open management expectations for this company. 1 open-market insider purchase recorded.

Mentioned in recent filings: Tariffs

What changed

Key figures

From the 10-Q for the period ended September 30, 2026, filed November 4, 2026. SEC

LatestEarlierChange
Revenue quarter$108B$103B+5.4%
Operating income quarter$3.6B−$3.2B+211.2%
Net income quarter$2.2B−$4B+154.6%
Diluted EPS quarter$1.68−$3.13+153.7%
Dividends per share quarter$0.67$0.670.0%
Operating cash flow year to date$15.3B$7.2B+111.3%
Cash and cash equivalents balance$11.7B$8.5B+38.9%

Next results expected around February 3, 2027 (estimate: the quarter ending about December 30, 2026 plus the 35 days the last report took). The company announces the actual date.

As the company tagged them in its filing (SEC XBRL). Quarter and year figures are compared with the same period a year earlier, balances with the previous balance sheet. Download CSV

Revenue by quarter, $B

97.7Q4 '24*2.4%94.6Q1 '253.6%98.9Q2 '252.4%103Q3 '25-3.1%106Q4 '25*2%100Q1 '264.7%106Q2 '264.4%108Q3 '263.3%
Bottom row: operating margin (operating income divided by revenue). Q4 = fiscal year minus the three quarters reported on their own. Revenue as the company tagged it in its SEC filings (XBRL). Guidance is the company's own, not our forecast.

Sector peers

How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.

CompanyLatest revenueRevenue YoYOperating margin
CVS Health Corp CVS$108B+5.4%3.3%
Unitedhealth Group Inc UNH$113B-0.4%5.8%
Mckesson Corp MCK$111B+7.6%1.4%
Cigna Group CI$73.7B+5.6%3.3%
Cardinal Health Inc CAH$67.5B+5.5%1.1%
Elevance Health, Inc. ELV$51.4B+1.4%2.5%
Johnson & Johnson JNJ$25.4B+5.9%—

Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.

Expectations and reality

Open

  • CVS Health intends to separate into two independent, publicly traded companies, a process expected to be completed in the first half of 2028.

    Said November 4, 2026 · Period named: first half of 2028 · Source · Our article

    Not yet checked against later reports.

  • The company expects to complete the separation in the first half of 2028, subject to conditions including board approval, effectiveness of a Form 10 registration statement, and tax-free treatment confirmation.

    Said November 4, 2026 · Period named: first half of 2028 · Source · Our article

    Not yet checked against later reports.

  • The company expects the separation into two independent companies to be completed in the first half of 2028, subject to customary conditions including board approval and effectiveness of a Form 10 registration statement.

    Said November 4, 2026 · Period named: first half of 2028 · Source · Our article

    Not yet checked against later reports.

What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.

Governance events

Filings about how the company is run: auditor changes, restatements, leadership changes, late filings, delistings, Schedule 13D stakes and SEC comment letters, newest first.

DateEventFiling
August 17, 2026Director or officer departure or appointment (8-K item 5.02)8-K

As filed with the SEC, read by code. A comment letter is part of the SEC staff’s routine review and does not by itself mean a problem; item 5.02 covers appointments as well as departures; Form 25 may concern a bond or another class of securities.

Insider trades

DatePersonTradeSharesAvg. priceValueFiling
November 6, 2026Prem S ShahPurchase23,855$83.90$2,001,315SEC

All insider trades →

Large funds (13F)

FundSharesValueChange in sharesQuarter
BlackRock120,390,157$10,316,232,599-2.3%Q3 2026
State Street60,087,270$5,148,878,166-0.3%Q3 2026
Wellington Management36,682,829$3,143,351,616+8.5%Q3 2026
Geode Capital Management30,921,045$2,638,142,619+3.4%Q3 2026
Fidelity (FMR)24,881,207$2,132,070,581-14.0%Q3 2026
Capital Research Global Investors21,853,140$1,872,682,211-10.2%Q3 2026
Norges Bank (Norway's sovereign fund)18,038,922$1,866,126,481—Q2 2026
Renaissance Technologies2,724,053$233,424,102+517.7%Q3 2026
Millennium Management1,495,249$128,127,887-30.9%Q3 2026
D. E. Shaw & Co.1,028,148$88,102,002-25.6%Q3 2026
Citadel Advisors815,797$69,905,645-83.0%Q3 2026
Bridgewater Associates378,152$32,403,845-14.2%Q3 2026
Two Sigma Investments134,635$11,536,873—Q3 2026
T. Rowe Price21,663,186$1,856,319-10.5%Q3 2026

From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.